Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?

Research output: Contribution to journalComment/debatepeer-review

5 Scopus citations
Original languageEnglish (US)
Pages (from-to)860-861
Number of pages2
JournalThe Lancet Oncology
Issue number7
StatePublished - Jul 2018
Externally publishedYes

Bibliographical note

Funding Information:
I am a paid consultant or advisor to Janssen, Astellas, Sanofi, Dendreon, Medivation, ESSA, AstraZeneca, Clovis, and Merck. I have received research funding to my institution from Janssen, Johnson & Johnson, Sanofi, Dendreon, Genentech, Novartis, Tokai, Bristol Myers-Squibb, AstraZeneca, Clovis, and Merck. I am the co-inventor of a biomarker technology that has been licensed to Qiagen. This work was partially supported by the National Institutes of Health (P30 CA006973) and the US Department of Defense (W81XWH-16-PCRP-CCRSA).

Cite this